Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures
Hisashi Hidaka(Kitasato University), Michio Imawari(Jichi Medical University), Takumi Igura, Masatoshi Kudo(Kindai University), Masataka Seike(Oita University), Toshimitsu Ochiai(Shionogi (Japan)), Takayuki Katsube(Shionogi (Japan)), Takahiro Fukuhara(Shionogi (Japan)), Kazuhiro Kimura(Yamaguchi University), Takeshi Kano(Shionogi (Japan)), Namiki Izumi(Musashino Red Cross Hospital), Toru Ishikawa(Saiseikai Niigata Daini Hospital), Masayuki Kurosaki(Musashino Red Cross Hospital), Mineo Kurokawa(University of Tokyo Hospital), Katsuaki Tanaka(Yokohama City University Medical Center), Hironori Tanaka(Hyogo Medical University), Kazuhide Yamamoto(Kurume University Medical Center), Seigo Abiru(Nagasaki Medical Center), Yukio Osaki(Osaka Red Cross Hospital), Tsutae Den Nagata(Shionogi (Japan))
Cited by 124
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k